Diabetic retinopathy and coronary implantation of sirolimus-eluting stents

J Interv Cardiol. 2007 Apr;20(2):122-31. doi: 10.1111/j.1540-8183.2007.00252.x.

Abstract

Introduction: The prognostic value of identifying the retinal status of diabetic patients undergoing coronary implantation of drug-eluting stents is unknown.

Methods: We evaluated the outcomes of 318 consecutive patients undergoing implantation of sirolimus-eluting stents for coronary artery disease. Patients were divided into 5 groups according to the diabetic and retinal status: diabetic patients without retinopathy (43 patients); diabetic patients with nonproliferative retinopathy (34); diabetic patients with proliferative retinopathy (37); diabetic patients with unknown retinal status (30); and nondiabetic patients (174).

Results: During a mean follow-up of 385 days, 64 patients had target-vessel failure (defined as a composite of death from cardiac causes, myocardial infarction, and target-vessel revascularization). At 1 year, Kaplan-Meier estimates of the rate of target-vessel failure were 15.3% for diabetic patients without retinopathy, 56.6% for those with nonproliferative retinopathy, 17.3% for those with proliferative retinopathy, 19.0% for those with unknown retinal status, and 16.0% for nondiabetic patients. After adjustment for the potential confounders and differences between groups, the relation of nonproliferative retinopathy to target-vessel failure remained significant. In an analysis in which diabetic patients without retinopathy were used as the reference group, the hazard ratios for target-vessel failure were 3.9 for those with nonproliferative retinopathy, 1.3 for those with proliferative retinopathy, 1.1 for those with unknown retinal status, and 1.4 for nondiabetic patients (P for trend = 0.015).

Conclusions: As compared with diabetic patients without retinopathy, those with nonproliferative retinopathy have an increased risk for target-vessel failure after coronary implantation of sirolimus-eluting stents.

MeSH terms

  • Aged
  • Case-Control Studies
  • Coronary Artery Disease / drug therapy
  • Coronary Artery Disease / surgery*
  • Diabetic Retinopathy* / complications
  • Diabetic Retinopathy* / diagnosis
  • Drug Delivery Systems*
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Middle Aged
  • Prognosis
  • Prospective Studies
  • Risk
  • Sirolimus / administration & dosage
  • Sirolimus / therapeutic use*
  • Stents*
  • Treatment Failure
  • Treatment Outcome*

Substances

  • Immunosuppressive Agents
  • Sirolimus